Inbar Carmeli currently serves as Chief of Staff to the CEO at YEDA - Technology Transfer Company of Weizmann Institute of Science since December 2023, following a role as Chief of Staff to the CEO at Quik from November 2022 to December 2023. Prior experience includes positions as Project Manager at the ERI Institute from January 2021 to October 2022, and at Teva Pharmaceuticals from 2014 to 2018, where responsibilities involved leading projects in corporate communications and global branding. Inbar spent 14 years with the Israeli Navy (2000-2014), holding various HR management roles, focusing on organizational planning and policy formulation. Educational background includes an MA in Labor Studies from Tel Aviv University and programs in Sustainable Global Leadership and Business Administration from Ruppin Academic Center.
This person is not in any teams
This person is not in any offices
YEDA - Technology Transfer Company of Weizmann Institute of Science
Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world. WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute. Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education. Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta. Yeda performs the following activities: ◣ Identifies and assesses research projects with commercial potential. ◣ Protects the intellectual property of WIS and its scientists. ◣ Licenses WIS' inventions and technologies to industry. ◣ Establishes new Startup companies based in WIS Intellectual Property ◣ Channels funding from industry to research projects. Our portfolio covers a broad spectrum of the natural sciences, including: ◣ Agriculture and Plant Genetics, including Bio-fuels ◣ Chemistry and Nanotechnology ◣ Environmental Sciences and Solar Energy ◣ Mathematics and Computer Science ◣ Medical Devices ◣ Pharmaceuticals and Diagnostics ◣ Physics and Electro-Optics ◣ Research Tools